https://www.selleckchem.com/pr....oducts/Phlorizin(Phl
m current ongoing Phase III trials will hopefully give light to this critical issue. Epidemiological studies have shown that 6.9-10% of people suffer from neuropathic pain, a complex painful condition which is often undertreated. Data regarding the effectiveness of treatment options for patients with neuropathic pain is inconsistent, and there is no single treatment option that shows cost-effectiveness across studies. In this narrative review, the authors present the results of different prospective, randomized controlled
Like
Comment
Share
